Released Aug 8, 2024, after the close
10-Q filed Aug 8, 2024, 39 days after period end · 0000950170-24-093998
Q2 2024 · 10-Q
Revenue$8.53M$8.53M — vs Q2 2023+47.5% vs Q1 2024
Net Income-$11.15M-$11.15M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$1.98-$1.98 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$12,203,000N/M
Operating Cash Flowderived-$17,102,000N/M
Free Cash Flowderived-$17,116,000N/M
Margins · derived
Operating margin-143.0%
Net margin-130.7%
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $8.53M | $0.00 | — | — |
| Net Income | -$11.15M | -$16.90M | -$24.46M | -$23.60M |
| EPS Diluted | -$1.98 | -$3.88 | -$0.51 | -$0.55 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR